Spotlight: Scios Shares Rise on Strong Heart Drug Study

Scios Inc. shares rose 24% after the company said it plans to file for U.S. Food and Drug Administration approval of its heart drug, Natrecor, based on the strength of a new study. Natrecor significantly improved heart functioning and patients’ symptoms, the Mountain View company said. Natrecor is a natural heart hormone that reduces fluid buildup and pressure, believed to be triggers for acute attacks. Scios’ shares rose $1.69 to close at $8.94 on Nasdaq.